{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:07:22Z","timestamp":1759018042886,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ophtha.2017.08.024","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T01:10:37Z","timestamp":1513559437000},"page":"e10-e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Singh et\u00a0al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785)"],"prefix":"10.1016","volume":"125","author":[{"given":"Bobeck S.","family":"Modjtahedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald S.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2017.08.024_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ophtha.2017.01.036","article-title":"Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies","volume":"124","author":"Singh","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.08.024_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjophthalmol-2016-308617","article-title":"Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy","volume":"101","author":"Pollack","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.024_bib3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/OPTH.S31902","article-title":"Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy","volume":"6","author":"Singh","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.024_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2016-309838","article-title":"The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema","author":"Denniston","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.08.024_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajo.2017.01.006","article-title":"Perioperative topical nonsteroidal anti-inflammatory drugs for macular edema prophylaxis following cataract surgery","volume":"176","author":"Modjtahedi","year":"2017","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017317645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017317645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:09:11Z","timestamp":1758982151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017317645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0161642017317645"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.024","relation":{},"ISSN":["0161-6420"],"issn-type":[{"type":"print","value":"0161-6420"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Singh et\u00a0al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785)","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.036","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}